Streetbeat News

Regulatory

MAIA

MAIA Biotechnology, Inc. (NYSE:MAIA) announced its participation in the International Biochemistry Congress 2023, where it will present the latest findings from a study of its second generation telomere-targeting agents derived from lipid-modified THIO molecules. The company's objective is to discover new compounds with improved specificity towards cancer cells and potentially increased anticancer activity. THIO is currently in Phase 2 human clinical trials for non-small cell lung cancer treatment.

Portfolio Pulse from Happy Mohamed

October 17, 2023 | 12:23 pm

ALHC

WBA

Alignment Healthcare, Inc. (NASDAQ:ALHC) and Walgreens (NASDAQ:WBA) have signed an agreement to offer new $0-premium co-branded Medicare Advantage plans in select markets throughout Arizona, California, Florida and Texas starting Jan. 1, 2024. The plans will reach approximately 1.6 million Medicare-eligible adults, pending regulatory approvals. The plans offer comprehensive medical and prescription drug coverage including a $0 copay on more than 10,000 prescription drugs at Walgreens and other in-network pharmacies.

Portfolio Pulse from Happy Mohamed

October 17, 2023 | 12:23 pm

NKGN

NKGen Biotech Inc. (NASDAQ:NKGN) presented interim Phase I trial data on its investigational NK cell therapy, SNK01, for Alzheimer's disease at the XXVI World Congress of Neurology. The trial evaluated the safety, tolerability, and exploratory efficacy of SNK01 in patients with mild cognitive impairment and Alzheimer's. The results showed that SNK01 has the potential to cross the blood-brain barrier and effectively reduce neuroinflammation, a critical factor in treating Alzheimer's. No treatment-related adverse events were observed.

Portfolio Pulse from Happy Mohamed

October 17, 2023 | 12:20 pm

VINE

Fresh Vine Wine, Inc. (NYSE:VINE) has submitted a plan of compliance to NYSE American to regain compliance with the exchange's minimum stockholders' equity requirements for continued listing. The company has reported losses in its last three fiscal years and currently has stockholders' equity of $2.4 million, below the required $4 million. Fresh Vine Wine is exploring strategic opportunities such as mergers or acquisitions to enhance stockholder value and has engaged The Oak Ridge Financial Services Group as its investment banker.

Portfolio Pulse from Happy Mohamed

October 17, 2023 | 12:19 pm

NXTC

NextCure, Inc. (NASDAQ:NXTC) has presented new preclinical data showing that its novel anti-Siglec-15 antibody, NC605, reduced bone loss and improved bone quality in mice with osteogenesis imperfecta (OI). The results support the development of NC605 as a potential treatment for OI, a rare disease causing bones to fracture easily.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:09 pm

ECOR

ElectroCore's GammaCore Therapy will continue to be listed in the U.K's National Health Service Supply Chain Catalogue for an additional two years until March 17, 2026. The listing, which commenced on June 4, 2019, was initially scheduled to terminate on March 18, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:03 pm

INMB

INmune Bio Inc. will present new biomarker and feasibility data from its Phase 1b study, supporting the use of XPro in treating Alzheimer's disease, at the Clinical Trials on Alzheimer's Disease Conference from October 24-27.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:01 pm

RZLT

The European Medicines Agency has granted Priority Medicines (PRIME) eligibility to Rezolute's RZ358 for the treatment of Congenital Hyperinsulinism. This could potentially expedite the development and review of the drug.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:01 pm

LSTA

Lisata Therapeutics has announced that the European Medicines Agency has granted orphan drug designation to LSTA1 for the treatment of pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:01 pm

VIGL

Vigil Neuroscience has initiated a Phase 1 trial in healthy volunteers to evaluate VG-3927, a potential treatment for Alzheimer's disease. The first participant has been dosed.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 11:46 am